Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Thalassemia D013789 8 associated lipids
Thrombasthenia D013915 4 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thrombocytosis D013922 4 associated lipids
Thrombosis D013927 49 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Toxemia D014115 3 associated lipids
Tumor Virus Infections D014412 8 associated lipids
Uremia D014511 33 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Viremia D014766 4 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Granulomatosis with Polyangiitis D014890 5 associated lipids
Wounds and Injuries D014947 20 associated lipids
Xeroderma Pigmentosum D014983 6 associated lipids
Dementia, Multi-Infarct D015161 2 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Reperfusion Injury D015427 65 associated lipids
Weight Gain D015430 101 associated lipids
Weight Loss D015431 56 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Leukemia, Eosinophilic, Acute D015472 3 associated lipids
AIDS Dementia Complex D015526 4 associated lipids
HIV Infections D015658 20 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Blood Loss, Surgical D016063 6 associated lipids
Milk Hypersensitivity D016269 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Helicobacter Infections D016481 21 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Corneal Neovascularization D016510 8 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Malaria, Falciparum D016778 22 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Colitis, Ischemic D017091 3 associated lipids
Liver Failure D017093 5 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Strongylida Infections D017206 5 associated lipids
Hypertrophy, Right Ventricular D017380 4 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Hillmar I and Zöllner N Saturated and unsaturated 1-0-alkyl-2-0-acetoyl-sn-glycero-3-phosphocholines and 2-lyso derivatives from ratfish liver oil. Effect on adenosine 3':5'-cyclic monophosphate concentration in hepatocyte suspensions. 1983 Res Exp Med (Berl) pmid:6310713
Mauco G et al. Platelet activating factor (PAF-acether) promotes an early degradation of phosphatidylinositol-4,5-biphosphate in rabbit platelets. 1983 FEBS Lett. pmid:6311620
Camussi G et al. Release of platelet activating factor in rabbits with antibody-mediated injury of the lung: the role of leukocytes and of pulmonary endothelial cells. 1983 J. Immunol. pmid:6311899
Hwang SB et al. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. 1983 Biochemistry pmid:6313047
Wasserman SI Mediators of immediate hypersensitivity. 1983 J. Allergy Clin. Immunol. pmid:6193157
Hopkins NK et al. Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. 1983 Biochim. Biophys. Acta pmid:6313071
Mencia-Huerta JM et al. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE. 1983 J. Immunol. pmid:6315819
Czarnetzki B Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. 1983 Clin. Exp. Immunol. pmid:6317241
Stimler NP and O'Flaherty JT Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. 1983 Am. J. Pathol. pmid:6624879
Kloprogge E et al. Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. 1983 Thromb. Res. pmid:6222507
Hartung HP Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. 1983 FEBS Lett. pmid:6309563
Shukla SD et al. Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. 1983 J. Biol. Chem. pmid:6309795
Hallam TJ et al. The role of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) and palmitoyl-lysophosphatidate in the responses of human blood platelets to collagen and thrombin. 1983 FEBS Lett. pmid:6617886
Heffner JE et al. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. 1983 J. Clin. Invest. pmid:6822668
Keraly CL et al. Effect of structural analogues of PAF-acether on platelet desensitization. 1983 Br. J. Haematol. pmid:6824590
Tence M et al. The enantiomer and the positional isomer of platelet-activating factor. 1983 Biochim. Biophys. Acta pmid:6824744
Camussi G et al. Biosynthesis and release of platelet-activating factor from human monocytes. 1983 Int. Arch. Allergy Appl. Immunol. pmid:6826235
Randolph AE et al. Blood pressure and heart rate effects of alkyl ether phospholipids in conscious renal, spontaneously hypertensive, and normotensive rats. 1983 Clin Exp Hypertens A pmid:6684006
Morley J et al. Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. 1983 Br. J. Pharmacol. pmid:6685552
Hornby EJ and Perry CR 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. 1983 Thromb. Haemost. pmid:6636035
Patterson R and Harris KE The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. 1983 J. Lab. Clin. Med. pmid:6644157
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Myers A et al. Glucocorticoid protection against PAF-acether toxicity in mice. 1983 Br. J. Pharmacol. pmid:6652344
Cervoni P et al. Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. 1983 Br. J. Pharmacol. pmid:6652348
Ogihara T et al. [Renomedullary hypotensive lipids and prostaglandins]. 1983 Horumon To Rinsho pmid:6368051
Lewis JC et al. Platelet-activating factor effects on pulmonary ultrastructure in rabbits. 1983 Exp. Mol. Pathol. pmid:6832335
Levy JV Calmodulin antagonists inhibit aggregation of human, guniea pig and rabbit platelets induced with platelet activating factor. 1983 FEBS Lett. pmid:6832368
Touqui L et al. Conversion of 3H-PAF acether by rabbit platelets is independent from aggregation: evidences for a novel metabolite. 1983 Biochem. Biophys. Res. Commun. pmid:6838557
Worthen GS et al. Platelet-activating factor causes neutrophil accumulation and edema in rabbit lungs. 1983 Chest pmid:6839840
Heffner JE et al. Platelet-induced pulmonary hypertension and edema. A mechanism involving acetyl glyceryl ether phosphorylcholine and thromboxane A2. 1983 Chest pmid:6839854
Levy JV Calmodulin antagonist W-7 inhibits aggregation of human platelets induced by platelet activating factor. 1983 Proc. Soc. Exp. Biol. Med. pmid:6844347
O'Flaherty JT et al. Platelet-activating factor and analogues: comparative studies with human neutrophils and rabbit platelets. 1983 Res. Commun. Chem. Pathol. Pharmacol. pmid:6844746
Valone FH and Goetzl EJ Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. 1983 Immunology pmid:6848449
Chilton FH et al. Metabolic fate of platelet-activating factor in neutrophils. 1983 J. Biol. Chem. pmid:6853486
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Kloprogge E et al. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. 1983 Thromb. Res. pmid:6857605
Chilton FH et al. Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. 1983 J. Biol. Chem. pmid:6408071
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Hartung HP et al. Platelet activating factor (PAF) induces the oxidative burst in macrophages. 1983 Int. J. Immunopharmacol. pmid:6874164
Gonzalez-Crussi F and Hsueh W Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. 1983 Am. J. Pathol. pmid:6859226
1st International Symposium on Platelet-Activating Factor (PAF-ACETHER, AGEPC) and structurally related ether-lipids. Paris (France) June 26-29, 1983. Abstracts. 1983 J Pharmacol pmid:6876807
Camussi G et al. Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. 1983 Am. J. Pathol. pmid:6859232
Cargill DI et al. Aggregation, release and desensitization induced in platelets from five species by platelet activating factor (PAF). 1983 Thromb. Haemost. pmid:6879508
Virella G et al. Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. 1983 Immunology pmid:6885111
Camussi G et al. Platelet-activating factor-mediated contraction of rabbit lung strips: pharmacologic modulation. 1983 Immunopharmacology pmid:6885382
Vermylen J et al. Normal mechanisms of platelet function. 1983 Clin Haematol pmid:6301715
Hubbard JW et al. Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats. 1983 Life Sci. pmid:6337313
Acharya SB and MacIntyre DE Platelet products and vascular PGI2 production. 1983 Prostaglandins Leukot Med pmid:6338532
Camussi G et al. Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. 1983 Immunology pmid:6339375
Billah MM and Lapetina EG Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. 1983 Proc. Natl. Acad. Sci. U.S.A. pmid:6341992